|
Index | - | P/E | - | EPS (ttm) | -26.93 | Insider Own | 7.10% | Shs Outstand | 1.17M | Perf Week | 4.35% |
Market Cap | 3.45M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 1.09M | Perf Month | -45.97% |
Income | -19.70M | PEG | - | EPS next Q | - | Inst Own | 1.90% | Short Float / Ratio | 1.73% / 0.43 | Perf Quarter | -52.79% |
Sales | 1.40M | P/S | 2.46 | EPS this Y | 3.70% | Inst Trans | 45.40% | Short Interest | 0.02M | Perf Half Y | -68.52% |
Book/sh | 10.85 | P/B | 0.27 | EPS next Y | - | ROA | -87.70% | Target Price | - | Perf Year | -88.66% |
Cash/sh | 0.34 | P/C | 8.61 | EPS next 5Y | - | ROE | -125.40% | 52W Range | 2.70 - 43.00 | Perf YTD | -40.62% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -93.30% | Beta | 1.45 |
Dividend % | - | Quick Ratio | 0.20 | Sales past 5Y | - | Gross Margin | - | 52W Low | 6.67% | ATR | 0.40 |
Employees | 17 | Current Ratio | 0.20 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 29.53 | Volatility | 5.95% 9.46% |
Optionable | Yes | Debt/Eq | 0.62 | EPS Q/Q | 18.70% | Profit Margin | - | Rel Volume | 0.56 | Prev Close | 2.92 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Nov 30 BMO | Payout | - | Avg Volume | 43.26K | Price | 2.88 |
Recom | - | SMA20 | -29.28% | SMA50 | -39.67% | SMA200 | -66.45% | Volume | 17,098 | Change | -1.37% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite